2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Bladder Cancer

Non-Muscle-Invasive Bladder Cancer: An Overview of Potential New Treatment Options - Beyond the Abstract

Intravesical Bacillus Calmette-Guérin (BCG) is an efficacious treatment for non-muscle-invasive bladder cancer (NMIBC) and was the first therapy to reduce the risk of recurrence and progression in high-risk NMIBC. Depending on the risk, approximately 70% of patients may achieve a complete response to BCG; however, up to 60% may experience recurrence after 1 year. For some clinics and their patients, the ongoing shortage of BCG is a variable affecting the management of BCG-naïve and BCG-recurrent/unresponsive NMIBC. In a recent article (Shore ND, et al. Urol Oncol 2021;39:642–63), we reviewed the literature to both assess and summarize clinical practice guidelines regarding disease definitions and risk stratifications, as well as the treatment decision-making for NMIBC. We reported novel therapies and combinations that have demonstrated promising antitumor activity in clinical trials, especially for high-risk or BCG-unresponsive NMIBC. Improvements in the detection, diagnosis, surveillance and treatment of NMIBC are resulting in better clinical patient outcomes.

This video was funded by Pfizer. Medical writing support was provided by Steven Moore, PhD, of Engage Scientific Solutions and was funded by Pfizer.

Non Muscle-Invasive Bladder Cancer: An Overview of Potential New Treatment Options - Beyond the Abstract



Written by: 

  • Neal D. Shore, MD, FACS, Chief Medical Officer, Surgery/Urology, for GenesisCare and the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina
  • Gary D. Steinberg, MD, Professor and Director of the Goldstein Bladder Cancer Program, NYU Langone Health, New York City, New York

Read the Abstract